
Releases
Regencell Investors Face June 23 Deadline in Securities Class Action
A pending class action lawsuit challenges the meteoric rise and subsequent volatility of Regencell Bioscience Holdings, alleging the company misled investors about its operational capacity. Shareholders who purchased securities between October 2024 and October 2025 have until June 23, 2026, to seek lead plaintiff status in the case.
























